| Not Yet Recruiting | Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC NCT07494435 | Zhejiang Haichang Biotech Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma NCT06773377 | Assiut University | — |
| Recruiting | Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy NCT07294859 | Jinling Hospital, China | — |
| Recruiting | Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations. NCT06903312 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 4 |
| Recruiting | Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma NCT06934057 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 4 |
| Recruiting | Using 3D Kidney Model Based on Artificial Intelligence to Assist Partial Nephrectomy: A Prospective Validation NCT07020169 | Shao Pengfei | N/A |
| Recruiting | Prehabilitation Prior to Surgery for Kidney Tumors NCT06745609 | Herlev and Gentofte Hospital | N/A |
| Recruiting | The Value of a Convolutional Neural Network-Based Renal Artery Perfusion Model in Predicting Renal Function Af NCT06751498 | Shao Pengfei | — |
| Recruiting | Optimising Renal Tumour Management Through Artificial Intelligence Modules NCT06714916 | Shao Pengfei | — |
| Recruiting | Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma NCT06676527 | Jinling Hospital, China | — |
| Recruiting | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369 | 7 Hills Pharma, LLC | Phase 1 / Phase 2 |
| Recruiting | A Study of IBI363 in Subjects with Advanced Solid Malignancies NCT06281678 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Recruiting | TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid NCT04969315 | Portage Biotech | Phase 1 / Phase 2 |
| Recruiting | Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Ana NCT04625556 | Yonsei University | — |
| Withdrawn | Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib NCT05263609 | University of Oklahoma | Phase 2 |
| Completed | A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of So NCT05363072 | Pfizer | — |
| Recruiting | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer NCT05329532 | Scancell Ltd | Phase 1 / Phase 2 |
| Terminated | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors NCT05061537 | Pfizer | Phase 1 |
| Active Not Recruiting | Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer NCT04620603 | Case Comprehensive Cancer Center | Phase 1 |
| Unknown | Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma NCT04714697 | Asan Medical Center | Phase 2 |
| Suspended | DNX-2440 for Resectable Colorectal Liver Metastasis NCT04714983 | DNAtrix, Inc. | Phase 1 |
| Unknown | WIRE - Novel Treatments in Renal Cell Cancer NCT03741426 | CCTU- Cancer Theme | Phase 2 |
| Withdrawn | Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma NCT04260360 | NanOlogy, LLC | Phase 1 |
| Recruiting | Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing NCT04197414 | Yonsei University | — |
| Completed | Fear of Cancer Recurrence in Genitourinary Cancer NCT04535921 | Ludwig-Maximilians - University of Munich | — |
| Completed | Fecal Microbiota Transplantation in Diarrhea Induced by Tyrosine-kinase Inhibitors NCT04040712 | Catholic University of the Sacred Heart | N/A |
| Active Not Recruiting | Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors NCT04258462 | Zhen Wang, MD | Phase 2 |
| Completed | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers NCT03454451 | Corvus Pharmaceuticals, Inc. | Phase 1 |
| Active Not Recruiting | Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Ca NCT03455452 | Bristol-Myers Squibb | — |
| Recruiting | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People NCT02830724 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | NANOTECH RCC Biomarkers NCT02923284 | Washington University School of Medicine | — |
| Completed | A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) NCT02684006 | Pfizer | Phase 3 |
| Completed | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezoli NCT02655822 | Corvus Pharmaceuticals, Inc. | Phase 1 |
| Terminated | ImmuniCell® in Patients With Advanced Cancers NCT02459067 | TC Biopharm | Phase 2 |
| Completed | A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100) NCT02493751 | Pfizer | Phase 1 |
| Terminated | Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papi NCT02495103 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib NCT02428335 | AHS Cancer Control Alberta | — |
| Terminated | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) NCT02423954 | Western Regional Medical Center | Phase 1 / Phase 2 |
| Completed | Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Interv NCT02375776 | Massachusetts General Hospital | N/A |
| Terminated | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) NCT02212730 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy. NCT01967407 | University of Magdeburg | Phase 1 / Phase 2 |
| Completed | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer NCT01631552 | Gilead Sciences | Phase 1 / Phase 2 |
| Terminated | Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Adv NCT02071719 | M. Labots | — |
| Completed | An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizin NCT01598597 | Genentech, Inc. | — |
| Completed | Urine Proteome of Surgical Patients and Healthy Volunteers NCT01538823 | Washington University School of Medicine | — |
| Completed | Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in C NCT01402089 | Markus Joerger | Phase 4 |
| Completed | A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer NCT01829841 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Completed | An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell NCT01392729 | Hoffmann-La Roche | — |
| Completed | An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatmen NCT01351571 | Hoffmann-La Roche | — |
| Completed | Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity NCT01163552 | St. Luke's-Roosevelt Hospital Center | Phase 2 |
| Completed | Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) NCT01122615 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | Temsirolimus-RCC-imaging NCT01246817 | Radboud University Medical Center | Phase 2 |
| Terminated | Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer NCT01507740 | Medical University Innsbruck | — |
| Unknown | Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib NCT00890110 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Completed | Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers NCT01079286 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 1 |
| Completed | Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors NCT00855452 | Hadassah Medical Organization | Phase 2 |
| Completed | A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cel NCT00796757 | Hoffmann-La Roche | Phase 2 |
| Completed | Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma NCT00509704 | Radboud University Medical Center | — |
| Completed | Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer NCT01189370 | University of Kansas Medical Center | Phase 2 |
| Completed | Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC NCT00979329 | Radboud University Medical Center | — |
| Completed | Bevacizumab in Metastatic Renal Cancer NCT02627144 | Hoffmann-La Roche | — |
| Completed | Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumo NCT00694096 | University of Utah | Phase 1 |
| Completed | A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell C NCT00520403 | Hoffmann-La Roche | Phase 2 |
| Completed | Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer NCT00465179 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Percutaneous Tumor Ablation Vs Partial Nephrectomy for Small Renal Mass: the Impact of Histologic Variant and NCT06829888 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Completed | Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer NCT00304460 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery NCT01158534 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Relationship of Ochratoxin A to Upper Urologic Cancers NCT00216801 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | — |
| Unknown | Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) NCT00184015 | University of Southern California | Phase 1 / Phase 2 |
| Unknown | Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated NCT02429440 | University Hospital Tuebingen | Phase 1 / Phase 2 |
| Completed | Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis NCT00172003 | Novartis Pharmaceuticals | Phase 4 |
| Completed | A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Ren NCT00738530 | Hoffmann-La Roche | Phase 3 |
| Terminated | Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carci NCT00311467 | Central European Cooperative Oncology Group | Phase 3 |
| Terminated | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation NCT00429026 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Study of ABT-751 in Patients With Renal Cell Cancer NCT00073112 | Abbott | Phase 2 |
| Withdrawn | Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma NCT00061178 | Genentech, Inc. | Phase 3 |